Compare GE Vernova Inc (GEV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs ResMed Inc. — how do they compare? GE Vernova Inc trades at $1,002.88 (market cap $266.16B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: GE Vernova Inc is far larger — about 8.3× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and ResMed Inc. for 51 Days on average.
| GEV | RMD | |
|---|---|---|
Market Cap | $266.16B | $31.89B |
Volume | 2,324,165 | 618,314 |
Sector | Industrials | Health |
52-Week High | $1.17K | $277.88 |
52-Week Low | $547.96 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $255.83B | $31.24B |
Dividend Yield | 0.2% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,007.77, up 1.07% with strong bullish technical momentum. The stock shows impressive fundamental growth with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and a $176B backlog. Analyst consensus remains strongly bullish with 22 buy ratings and a $1,270 price target, representing 26% upside potential from current levels.
The outlook remains positive given the company's positioning in AI-driven power infrastructure demand, though valuation multiples appear elevated with P/E at 28.65 and EV/EBITDA at 85.22. Key risks include execution challenges in the wind segment and competitive pressures in the nuclear energy space. The stock's recent 45% YTD gain suggests much optimism is already priced in, requiring continued strong execution to justify further upside.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
